Canada’s prohibitions on cosmetic animal testing enter into force in December, largely in line with EU, California and other bans around the globe, but with some notable distinctions. “Now it's really time to increase the pressure in the US – action can't be far behind,” says Brandi Halls, chief ethics officer at Lush Cosmetics, North America.
Beginning on 22 December, no cosmetic product will be permitted for sale in Canada unless its safety can be substantiated without the use of data derived from animal testing after that date.
Passed as part of the Budget Implementation Act (C-47) on 22 June, Canada’s cosmetic animal-testing ban aligns closely with...
Country Life Vitamins launches healthy aging support line as it announces less than half of US consumers in a recent survey were aware of biological processes that affect aging. Groupe Berken and Arctic Biosciences partner to bring to North America herring caviar oil extract in a supplement designed to support optimal health across all life stages.
After launching Retaine MGD Advanced, OcuSoft says a release by Bruder Healthcare referenced Retaine MGD trademark and statements from a previous OcuSoft announcement about the original product attributed to an optometrist. B+L, Rohto brand and homeopathic firm Relief Products also make US OTC eye care space moves.
Masdel expects its Original Magic Bag hot or cold compress to catch on as a popular as well as effective product from north of the border.
Wild.AI women's health and wellness app available on Zepp’s Amazfit Active; WAT Medical’s app helps users lose weight; and firm Cronometer adds feature to answer users’ most frequent question, "How do I track water?"
The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”
US FDA Office of New Drugs Director Peter Stein says review divisions have made the case that a discussion-only meeting would solicit the necessary input.
Requests for “enforcement actions are not within the scope of FDA’s citizen petition procedures,” CDER says, rejecting petition dosing device firm Parenteral Technologies submitted as it prepares for workshop on Pediatric Research Equity Act requirements for OTC NDA sponsors.
